Runway Growth Finance (RWAY) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
A special meeting is scheduled for January 23, 2025, to approve a new investment management agreement due to a change in control of the investment adviser, with no changes to management, investment strategy, or fee structure expected.
The new agreement is required as the adviser's ownership will transfer to a BC Partners-affiliated entity, but all key personnel and services will remain unchanged.
The Board unanimously recommends approval, citing benefits such as enhanced access to capital, expanded origination channels, and potential operational efficiencies.
Stockholders will also vote on the election of a new director and the potential adjournment of the meeting if more votes are needed.
Voting matters and shareholder proposals
Proposals include approval of the new advisory agreement, election of Catherine Frey as director, and adjournment of the meeting if necessary.
The new advisory agreement proposal requires a majority of outstanding voting securities for approval; the director proposal requires a plurality of votes cast.
The adjournment proposal allows the meeting to be postponed to solicit additional proxies if needed.
The Board, including all independent directors, unanimously recommends voting in favor of all proposals.
Board of directors and corporate governance
The Board consists of five members, with a majority being independent as required by Nasdaq and the 1940 Act.
Catherine Frey is nominated to replace a resigning director, maintaining compliance with regulatory requirements for board independence.
The Board has Audit, Nominating and Corporate Governance, and Compensation Committees, all composed solely of independent directors.
The Board meets regularly, and independent directors hold executive sessions without management.
Latest events from Runway Growth Finance
- Lower Q4 2025 income, strong portfolio, and SWK deal to drive future growth.RWAY
Q4 202512 Mar 2026 - Q2 2024 featured strong new investments, robust yields, and active capital return programs.RWAY
Q2 20241 Feb 2026 - Q3 2024 saw $75.3M in new loans, strong yields, and a strategic adviser acquisition pending.RWAY
Q3 202414 Jan 2026 - $220M NAV-for-NAV merger boosts healthcare exposure and scale, closing by early 2026.RWAY
M&A Announcement7 Jan 2026 - NAV per share rose to $13.79 in 2024, with strong yields and expanded growth capacity.RWAY
Q4 202425 Dec 2025 - Shareholders will vote on director elections and auditor ratification at the 2024 virtual meeting.RWAY
Proxy Filing2 Dec 2025 - Shareholders to vote on a new advisory agreement after Adviser change in control, with no fee changes.RWAY
Proxy Filing2 Dec 2025 - Annual meeting to elect directors and ratify auditor, with board support for all proposals.RWAY
Proxy Filing2 Dec 2025 - Shareholders are urged to vote "FOR" three board-backed proposals at the January 2026 meeting.RWAY
Proxy Filing2 Dec 2025